Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus GENTAMICIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus GENTAMICIN SULFATE.
AMIKIN vs GENTAMICIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
1-2 mg/kg IV every 8 hours or 3-5 mg/kg IV every 24 hours for extended-interval dosing; typical duration 7-10 days.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 24-72 hours in renal impairment.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal excretion of unchanged drug accounts for >90% of elimination; biliary/fecal <2%.
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic